Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- GSK and Others See Massachusetts Showdown Over Drug-Marketing Reform
- There are two ideas floating in the world of politics to curb the way drug companies give doctors gifts and often biased information. One of them is a good idea, and one of them is a bad idea. Drug companies -- such as GlaxoSmithKline -- have chosen...
- Blog posts 2008-08-08
- Oxymoron No More: The Potential of Nonprofit Drug Companies to Deliver on the Promise of Medicines for the Developing World
- Although some pharmaceutical company efforts to develop and distribute drugs in developing countries have been successful, many fall short of meeting needs in resource-poor nations. The paper discusses the concept of a nonprofit pharmaceutical company dedicated to developing and distributing drugs for diseases endemic in developing countries. Using the experience...
- White papers 2005-08-01
- Drug Companies' Health Education Campaigns No Longer Speak Spanish
- For the first time in at least three years, drug companies have spent zero dollars on Spanish-language television for their unbranded health education ads, Nielsen-Monitor Plus reports. The wholescale write-off of Hispanic TV draws attention to how little Spanish-language provision there is in drug marketing. Of the...
- Blog posts 2008-10-03
- Wyeth v. Levine's Unintended Consequences: Prescription Data-Mining Banned in Vermont
- A federal court in Vermont has upheld a law preventing drug companies from "data-mining" prescription information from pharmacies. The court cited the U.S. Supreme Court's Wyeth v. Levine anti-preemption ruling as one of its reasons in doing so, suggesting that the Wyeth decision will consequences far beyond personal injury class-actions....
- Blog posts 2009-04-27
- Novartis, Boehringer Start Using Twitter Accounts
- AstraZeneca, Novartis, Vertex Pharmaceuticals and Boehringer Ingelheim have started experimenting with Twitter with varying degrees of enthusiasm, reports Pharmaceutical Executive. Drug companies have so far looked at social media with a mixture of fear and loathing. They believe perhaps wrongly that giving consumers more opportunities to talk...
- Blog posts 2009-02-18
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
Additional Resources
- FDA Expands Use of Convera Search Technology for Drug Review and Approval Process
- VIENNA, Va. -- Convera (NASDAQ:CNVR), a leading provider of search and categorization software for enterprises and government agencies, today announced expanded use of the company's RetrievalWare search technology by approximately 2,500 scientific review staff within the Center for Drug Evaluation and Research CDER at the FDA. The FDA's CDER uses...
- Research articles 2004-06-22
- Agilent Technologies Partners With Proteome Systems for Glycomics Applications, Software Development; Collaboration to Hasten Drug & Diagnostic Marker Discovery
- SYDNEY, Australia & PALO ALTO, Calif. -- Proteome Systems Ltd. (ASX:PXL), the globally recognized discovery, diagnostics and drug development company, and Agilent Technologies Inc. (NYSE:A) today announced the expansion of their cooperative marketing agreement to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics...
- Research articles 2006-08-09
- Earnings Won't Meet Expectations at Brentwood, Mo., Drug Development Firm.
- By Rachel Melcer, St. Louis Post-Dispatch Knight Ridder/Tribune Business News Jan. 8--Tripos Inc.'s shares are down 71 percent from a year ago, and the company warned this week that 2002 earnings won't meet expectations -- yet executives say the business is healthy....
- Research articles 2003-01-08
- St. Louis County software company settles class-action securities
- A federal judge on Friday approved the $3.15 million settlement of a class-action securities lawsuit against Tripos Inc., a drug- development services and software company based in St. Louis County. The lawsuit alleged Tripos violated the Securities Exchange Act of 1934 by misleading the public through press releases...
- Research articles 2006-08-08
- St. Louis County software company settles class-action securities suit for $3.15M
- A federal judge on Friday approved the $3.15 million settlement of a class-action securities lawsuit against Tripos Inc., a drug- development services and software company based in St. Louis County.The lawsuit alleged Tripos violated the Securities Exchange Act of 1934 by misleading the public through press releases and SEC filings...
- Research articles 2006-08-08
- Revlon OTC drug process, computer, cleaning cited
- Revlon's Oxford, NC, facility, which makes cosmetics, toiletries and sunscreens, the latter being an OTC drug, was cited for process, cleaning and software validation, among other problems during a March audit, according to FDA records. The facility, which had not had a GMP audit since 1991, had "numerous deficiencies,"...
- Research articles 2000-01-01
- St. Louis County software company settles class-action securities
- (This article was originally published in St. Louis Daily Record, another Dolan Media publication). A federal judge on Friday approved the $3.15 million settlement of a class-action securities lawsuit against Tripos, a drug- development services and software company based in St. Louis County. The lawsuit alleged...
- Research articles 2006-08-09
- Galt Names Bruce Hayden Chief Financial Officer; New CFO to Strengthen Fast-Growing Drug Safety Company's Executive Team
- Business/Technology Editors and Health/Medical Writers STERLING, Va.--BW HealthWire--June 17, 2002 Galt Associates, Inc., provider of drug safety and marketing software and services, announced today that it has appointed Bruce Hayden as chief financial officer. Mr. Hayden will play a prominent role in driving Galt's revenue, which experienced a...
- Research articles 2002-06-17
- An Update on Structuring Venture Capital and Other Investments in India
- Many U.S. and other foreign investors are evaluating alternatives for investments into software development, business process outsourcing ("BPO"), drug discovery, and other service companies in India. Despite news stories about U.S. venture capitalists traveling to India to look for investments in Indian companies, both U.S. and India venture capitalists tend...
- White papers 2004-11-22
- Invitrogen Launches Vector NTI® Advance™ 10; Release Includes Vector NTI® Open Access Policy and Vector NTI® User Community to Drive Life Science Standardization
- CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, today announced the release of its latest technology and eScience contribution to the life sciences, Vector NTI AdvanceTM 10. Centering on its...
- Research articles 2005-09-28
- H-E-B Moves to Active Data Warehousing with Help From Teradata; Action Will Enable Retailer to Make Better Marketing and Operations Decisions Faster — Strategic Decision Furthers Relationship with Teradata; Replaces Oracle Database
- SAN ANTONIO -- H-E-B, a food and drug retailer known for its innovative use of technology, is implementing a series of new infrastructure tools from Teradata, a division of NCR Corporation (NYSE:NCR), that will dramatically improve the company's ability to act and react to trends in the market. The transaction...
- Research articles 2005-09-20
- Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you sir. [Operator’s instructions.] One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed. Ross Muken – Deutsche Bank Good morning everyone. Mark P. Stevenson –...
- Earnings calls 2007-10-25
- AspenTech in Product Launches.(software aids FDA compliance)(Brief Article)
- AspenTech has released new software products that provide drug and other process manufacturers solutions for compliance with the Food & Drug Administration's electronic record and signature requirements. The company has also launched Aspen Ente AspenTech has released new software products that provide drug and...
- Research articles 2001-10-29
- Tripos' SYBYL 7.0 Discovery Software Suite Now Available; Molecular Modeling and Computational Chemistry Software for Drug Discovery
- ST. LOUIS -- Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery informatics products and chemistry research, today announced the release of SYBYLR 7.0, the latest version of its expert molecular modeling environment for drug discovery research. Tripos' longstanding customer-focused approach enables the company to offer the new software release...
- Research articles 2004-10-05
- << Previous
- page 1 of 1
- Next >>
Presented by American Express